347
Participants
Start Date
May 31, 2008
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
ABT-874
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
etanercept
SQ injection 50 mg BIW
placebo
SQ placebo injections for ABT-874 and etanercept
Site Reference ID/Investigator# 9761, Hershey
Site Reference ID/Investigator# 8471, Philadelphia
Site Reference ID/Investigator# 8472, Norfolk
Site Reference ID/Investigator# 8456, Greer
Site Reference ID/Investigator# 8463, Alpharetta
Site Reference ID/Investigator# 9641, Miami
Site Reference ID/Investigator# 8458, Goodlettsville
Site Reference ID/Investigator# 8460, Cleveland
Site Reference ID/Investigator# 8468, Cincinnati
Site Reference ID/Investigator# 8467, Indianapolis
Site Reference ID/Investigator# 8479, Arlington Heights
Site Reference ID/Investigator# 9001, Skokie
Site Reference ID/Investigator# 8466, West Dundee
Site Reference ID/Investigator# 8527, Schaumburg
Site Reference ID/Investigator# 8459, St Louis
Site Reference ID/Investigator# 9762, Oklahoma City
Site Reference ID/Investigator# 8482, Tyler
Site Reference ID/Investigator# 8452, Houston
Site Reference ID/Investigator# 8474, San Antonio
Site Reference ID/Investigator# 8461, Austin
Site Reference ID/Investigator# 8476, Denver
Site Reference ID/Investigator# 8478, Tucson
Site Reference ID/Investigator# 8447, Albuquerque
Site Reference ID/Investigator# 8454, Los Angeles
Site Reference ID/Investigator# 8462, Fresno
Site Reference ID/Investigator# 8480, Lake Oswego
Site Reference ID/Investigator# 8469, Portland
Site Reference ID/Investigator# 9566, Portland
Site Reference ID/Investigator# 8464, Boston
Site Reference ID/Investigator# 8473, East Windsor
Site Reference ID/Investigator# 8457, New Brunswick
Site Reference ID/Investigator# 8475, New York
Site Reference ID/Investigator# 8449, Johnston
Site Reference ID/Investigator# 8448, Providence
Site Reference ID/Investigator# 10542, Dallas
Collaborators (1)
Paragon Biomedical
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY